


LEGEND-T2DM Evidence Dissemination Summary

Target: **dapagliflozin**, Comparator: **empagliflozin** Outcome: **Venous thromboembolic events**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	4,444	3,332	23	6.90
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	140,812	100,335	357	3.56
Merative CCAE	14,296	11,031	44	3.99
Merative MDCCD	1,371	636	8	12.59
Merative MDCR	975	557	5	8.98
Optum Clinformatics	6,421	3,009	41	13.63
Optum EHR	9,746	2,227	20	8.98
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

